Genomatix Microarray Analysis Pipeline achieves Affymetrix GeneChip compatible?status
Genomatix Software GmbH today announced that it has achieved GeneChip-compatible GeneChip® microarray platform and that it has joined Affymetrix GeneChip-compatible Applications Program, which provides customers with a broad spectrum of software solutions for biomedical research and development. As a GeneChip-compatible...Inacom Information Systems achieves Cisco Systems Partner -Gold Certified status
MADISON , verifies a company has gained expertise in three specializations in addition to achieving...Third Wave Achieves Milestone, Delivers 200,000 SNP Assays to RIKEN In Japan
MADISON, Wis. -- Since the beginning of 2003, Third Wave has been supplying its Invader SNP assays to Dr. Yusuke Nakamura, group directo...Human Genome Project Achieves Technological Triumph
The completion of rough draft sequence of the human genes is a major scientific milestone and was achieved on 26.06.2000. The project began more than 10 years ago to map out almost 35 billion chemical letters that make up the recipe of human life. This breakthrough is expected to revolutionize the practice of medicine by paving the way for new drugs and medical therapies.Specific sequ...A Village in Madhya Pradesh Achieves Total Sanitation
Tarawata village in Madhya Pradesh's Guna district stands apart from other villages - it's spick and span. This has been made possible through the Total Sanitation// Campaign (TSC) launched by the administration almost six months back. Slogans propagating sanitary habits and cleanliness adorn its walls. The alleys passing through the nearly 200 'pucca' (concrete) houses are bereft of...Cethromycin Achieves Primary Endpoint in Pivotal Phase 3 Pneumonia Clinical Trial
CHICAGO, June 21, 2007 /PRNewswire-FirstCall/ -- Advanced LifeSciences Holdings, Inc. , today announced positive results fromTrial CL-06, the first of two pivotal Phase 3 clinical trialsdesigned to assess the safety and effectiveness of cethromycin, anovel once-a-day antibiotic, for the treatment of communityacquired pneumonia (CAP). In the study, cethromycin achievednon-inferiority in i...Micromet Achieves Milestone in BiTE Research Collaboration with MedImmune
CARLSBAD, Calif., April 23, 2007 /PRNewswire-FirstCall/Micromet, Inc. today announced the achievement of a milestone inits research collaboration with MedImmune, Inc. for the developmentof new BiTE(R) molecules targeting carcinoembryonal antigen (CEA),a validated tumor- associated antigen frequently expressed onvarious human carcinomas. Preclinical data recently presented atthe 2007 Annu...